NBIX - Neurocrine Biosciences Inc

Stock Details

Neurocrine Biosciences Inc (NBIX), a prominent company in the life sciences sector within the biological products, (no disgnostic substances) industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $141.87. Over the past 52 weeks, it has ranged between $84.23 and $154.61. This places the current price at 91.8% of its 52-week high and 68.4% above its 52-week low. Recent trading volume was recorded at 485,690. The 14-day Relative Strength Index (RSI) stands at 70.48, suggesting overbought conditions. The stock is currently trading above its 50-day moving average of $123.74 by 14.65%. Similarly, it is above its 200-day moving average of $121.92 by 16.36%. The MACD histogram is 0.49, indicating bullish momentum (MACD Line: 2.99, Signal Line: 2.50).

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

41.30

Above market average

Forward P/E

27.10

Earnings expected to grow

PEG Ratio

0.27

Potentially undervalued

Price to Book

5.14

EV/EBITDA

23.89

EPS (TTM)

$3.38

Price to Sales

5.52

Beta

0.25

Less volatile than market

How is NBIX valued relative to its earnings and growth?

Neurocrine Biosciences Inc trades at a P/E ratio of 41.30, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 27.10 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 0.27 suggests the stock may be undervalued relative to its growth rate.

What is NBIX's risk profile compared to the market?

With a beta of 0.25, Neurocrine Biosciences Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 5.14 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

13.90%

Operating Margin

21.20%

Return on Equity

13.40%

Return on Assets

8.67%

Revenue Growth (YoY)

16.50%

Earnings Growth (YoY)

68.30%

How profitable and efficient is NBIX's business model?

Neurocrine Biosciences Inc achieves a profit margin of 13.90%, meaning it retains $13.90 from every $100 in revenue after all expenses. This represents a solid margin typical of well-run businesses, showing the company can effectively balance revenue generation with cost control. The operating margin of 21.20% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 13.40% and ROA at 8.67%, the company achieves moderate returns on invested capital.

What are NBIX's recent growth trends?

Neurocrine Biosciences Inc's revenue grew by 16.50% year-over-year, showing steady progress in growing the business. This positive trajectory indicates the company maintains competitive positioning in its markets. Earnings increased by 68.30% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry averages for proper context.

Company Size & Market

Shares Outstanding

99.18M

Book Value/Share

$27.21

Asset Type

Common Stock

What is NBIX's market capitalization and position?

Neurocrine Biosciences Inc has a market capitalization of $13.85B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 99.18M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry, it competes with other firms in this sector.

How does NBIX's price compare to its book value?

Neurocrine Biosciences Inc's book value per share is $27.21, while the current stock price is $141.87, resulting in a price-to-book (P/B) ratio of 5.21. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$167.87

18.33% upside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

How reliable are analyst predictions for NBIX?

26 analysts cover NBIX with 88% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $167.87 implies 18.3% upside, but targets are often adjusted to follow price moves rather than predict them.

What is the Wall Street consensus on NBIX?

Current analyst recommendations:6 Strong Buy, 17 Buy, 3 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Sep 1, 2025, 05:42 AM

Technical Indicators

RSI (14-day)

70.48

Overbought

50-Day Moving Average

$123.74

14.65% above MA-50

200-Day Moving Average

$121.92

16.36% above MA-200

MACD Line

2.99

MACD Signal

2.50

MACD Histogram

0.49

Bullish

What does NBIX's RSI value tell investors?

The RSI (Relative Strength Index) for NBIX is currently 70.48, indicating the stock is in overbought territory (above 70). This suggests strong recent buying pressure that may be unsustainable. While overbought conditions can persist in strong trends, traders often watch for RSI divergences or a drop below 70 as potential sell signals. Combined with the price being above the 50-day moving average, this confirms bullish conditions.

How should traders interpret NBIX's MACD and moving average crossovers?

MACD analysis shows the MACD line at 2.99 above the signal line at 2.50, with histogram at 0.49. This bullish crossover suggests upward momentum is building. The 50-day MA ($123.74) is above the 200-day MA ($121.92), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Jul 15, 2025, 12:30 AM

Neurocrine Biosciences Inc (NBIX) Stock